Clinical Trials Browser

Recruiting × Breast Neoplasms × Docetaxel × Clear all

NCT07102381 2026-03-12

EmpowHER 208

Phase 2 Recruiting

Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Phase 2 Recruiting

Breast Neoplasms

NCT07358806 2026-01-22

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

BreastGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Phase 2 Recruiting

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05645380 2025-10-07

NeoTRACT

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05381038 2025-09-23

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Phase 1/2 Recruiting

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Phase 3 Recruiting

Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

Phase 2 Recruiting

Breast Neoplasms

NCT06441890 2025-07-14

BRE-10

Phase 2 Recruiting

Breast Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06769425 2025-06-24

HS-10502

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05838066 2025-05-30

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Phase 3 Recruiting

Breast Neoplasms

NCT05475678 2025-01-23

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04540692 2024-06-04

NEOSAMBA

Phase 3 Recruiting

Breast Neoplasms

NCT06254690 2024-02-12

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Phase 2 Recruiting

Breast Neoplasms

NCT05159193 2024-02-02

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT05978648 2023-11-30

SMA-BC-002

Phase 2 Recruiting

Breast Neoplasms

NCT05430399 2023-07-13

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT05638594 2023-03-20

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT04136782 2021-07-20

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Phase 4 Recruiting

Breast Neoplasms